Makary Resigns as FDA Commissioner Following Policy Disputes
-
By
-
Kathryn Wighton
-
May 12, 2026
-
2 min
By
Kathryn Wighton
May 12, 2026
The first at-home subcutaneous treatment for thyroid eye disease met its primary end point in 1 of 2 phase 3 trials.
by Mouj Hijazi
October 16, 2026
Participants exposed to inaccurate postevent summaries were less likely to correctly remember key details from videos they had previously watched.
September 30, 2026
Nearly 1 in 3 participants discontinued the yearlong dietary program because of diet-related challenges, despite a 61% completion rate.
October 30, 2026